Neurogene Inc. (NASDAQ:NGNE) Receives $44.00 Consensus Price Target from Analysts

Neurogene Inc. (NASDAQ:NGNE) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $44.00.

NGNE has been the subject of a number of research reports. Canaccord Genuity Group began coverage on Neurogene in a research report on Friday, February 27th. They set a “buy” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Neurogene in a research note on Tuesday, January 13th. Wall Street Zen lowered Neurogene from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Lifesci Capital initiated coverage on Neurogene in a research note on Monday, January 26th. They issued an “outperform” rating and a $50.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd.

Neurogene Stock Down 3.2%

Shares of NASDAQ:NGNE opened at $22.30 on Tuesday. The firm has a fifty day moving average of $19.02 and a two-hundred day moving average of $21.57. Neurogene has a 12-month low of $6.88 and a 12-month high of $37.27. The firm has a market capitalization of $345.43 million, a P/E ratio of -5.43 and a beta of 1.53.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its holdings in Neurogene by 89.8% in the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Neurogene by 43.6% during the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock valued at $61,000 after buying an additional 1,232 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in Neurogene during the fourth quarter valued at about $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after buying an additional 1,059 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Neurogene during the 4th quarter worth about $165,000. Institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.